Publications

SELECTED PUBLICATIONS BY STANFORD MCLP AND COLLABORATORS

  • Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, Zehnder A, Ohgami R, Kulkarni S, Armstrong R, Gratzinger D, Tavallaee M, Rook A, Snyder M, Kim Y, Khavari P. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet 47:1056-60, 2015.
  • Torrey H, Khodadoust M, Tran L, Baum D, Defusci A, Kim YH, Faustman DL. Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary Syndrome. Leukemia 33:1206-1218, 2019.
  • Qu K, Zaba LC, Satpathy AT, Giresi PG, Jin Y, Armstrong R, Jin C, Schmitt N, Rahbar Z, Ueno H, Greenleaf WJ, Kim YH, Chang HY. Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell 32:27-41, 2017.
  • Satpathy AT, Saligrama N, Buenrostro JD, Wei Y, Wu B, Rubin AJ, Granja JM, Lareau CA, Li R, Qi Y, Parker KR, Mumbach MR, Serratelli WS, Gennert DG, Schep AN, Corces MR, Khodadoust MS, Kim YH, Khavari PA, Greenleaf WJ, Davis MM, Chang HY. Transcript-indexed ATAC-seq for precision immune profiling. Nat Med 24:580-90, 2018.
  • Weng W-K, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH: Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Sci Transl Med 5(214):214ra171, 2013.
  • Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, Shizuru J, Muffly L, Meyer E, Negrin RS, Wang E, Almazan T, Million L, Khodadoust M, Li S, Hoppe RT, Kim YH. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv 4:4474-4482, 2020.
  • Dai J, Almazan TH, Hong EK, Khodadoust MS, Arai S, Weng WK, Kim YH. Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and Sézary syndrome. JAMA Dermatol 154: 728-730, 2018.
  • Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Granger P, Duvic M, Kim YH. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of pooled analysis from 3 phase II clinical trials. J Am Acad Dermatol 72:286-92, 2015.
  • Fong S, Hong EK, Khodadoust MS, Shufeng L, Hoppe RH, Kim YH, Hiniker SM. Low-dose total skin electron beam therapy combined with mogamulizumab for refractory mycosis fungoides and Sezary syndrome. Advances Rad Oncol. 2020, accepted Nov; available online D-20-00319R1
  • Kim YH, Hoppe RH, Rook AH, Maity A, Geskin L, Horowitz D, et al. A single-arm phase 2A study of NM-IL-12 in patients with mycosis fungoides-type CTCL undergoing low-dose total skin electron beam therapy. Blood 128(22);4165, 2016.
  • Obeid JP, Gutkin PM, Lewis J, SkinnerL, Wang EB, Khodadoust MS, Kim YH, Weng WK, Hoppe RT, Hiniker SM. Volumetric Modulated Arc Therapy and 3-Dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs. Pract Radiat Oncol 9:220-225, 2019.
  • Kim YH, Tavallaee MT, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RA, Horwitz SM. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable Cd30 expression level: a multi-institution collaborative project. J Clin Oncol, 33:3750-3758, 2015.
  • Prince HM*, Kim YH*, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma: an open-label, multicenter, randomized phase 3 trial. Lancet 390:555- 566, 2017. *Equal contribution.
  • Rahbar Z, Li S, Tavallaee M, Novoa RA, Kim J, Kim YH. Variability in the expression of immunohistochemical markers: implications for biomarker interpretation in cutaneous T-cell lymphoma. J Invest Dermatol 138:1204-1206, 2018.
  • Kim YH, Bagot M, Pinter-Brown P, Rook AH, Porcu P, Horwitz S, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, et al, and the MAVORIC Study Group. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase 3 trial. Lancet Oncol 19:1192-1204, 2018.
  • Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA, Kim YH. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphomas: an international, first-in-huma, open-label, phase 1 trial. Lancel Oncol 20:1160-1170, 2019.
  • Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, KimYH. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. J Clin Oncol 38:20-28, 2020.
  • Fernandez-Pol S, Petersen B, Murphy JE, Oak JS, Wang EBK, Rieger KE, Kim YH, Khodadoust MS, Suarez CJ. Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations. Am J Surg Pathol. 2020 Oct 14.
  • Rojansky R, Fernandez-Pol S, Wang E, Rieger KE, Novoa RA, Zehnder JL, Kunder CA, Kim YH, Khodadoust MS, Brown RA. Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports. Diagn Pathol 15:122, 2020.
  • Wang JY, Hirotsu KE, Neal TM, Raghavan SS, Kwong BY, Khodadoust MS, Brown RA, Novoa RA, Kim YH, Rieger KE. Histopathologic Characterization of Mogamulizumab-associated Rash. Am J Surg Pathol 44:1666-1676, 2020.
  • Hirotsu KE, Neal TM, Khodadoust MS, Wang JY, Rieger KE, Strelo J, Hong E, Kim YH, Kwong BY. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides and Sézary syndrome. JAMA Dermatology 157:700- 707, 2021.
  • Hoffmann JC, Atwater SK, Hong E, Kumar J, Khodadoust M, Kim Y, Ohgami RS. A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. Am J Dermatopathol 2020 42:389-396, 2020.
  • Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood G, Beylot-Barry M, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala M, Estrach T, Papadavid E, Antoniou C, Sugaya M, Miyagaki T, Gniadecki R, Saches J, Miyashiro D, Servitje O, Berti E, Onida F, Hodak E, Amitay-Laish I, Ortiz-Romero P, Rodriguez-Peralto J, Knobler R, Pimpinelli N, Cowan R, Rook A, Kim E, Pileri A, Pujol R, Wong H, Tyler K, Querfeld C, Willemze R, Evison F, Morris S, Kim J, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium (CLIC) Study of Outcome in Advanced Stages of Mycosis Fungoides & Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33:3766-73, 2015.
  • Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Vermeer M, Bagot M, Guitart J, Papadavid L, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Octavio S, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim YH. Global patterns of care in advanced stage MF/SS: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (CLIC). Ann Oncol 28:2517-25, 2017.
  • Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, DiCaudo DJ, Shinohara M, Hong EK, Horton B, Kim YH. The use of central pathology review with digital slide scanning in advanced stage mycosis fungoides and Sezary syndrome: a multi-institutional and international pathology study. Am J Surg Pathol 42:726-34, 2018.
  • Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei- A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 181:350-357, 2019.
  • Hodak E, Sherman S, Papadavid E, Bagot M, Querfeld C, Quaglino P, Prince HM, Ortiz-Romero PL, Stadler R, Knobler R, Guenova E, Estrach T, Patsatsi A, Leshem YA, Prague-Naveh H, Berti E, Alberti-Violetti S, Cowan R, Jonak C, Nikolaou V, Mitteldorf C, Akilov O, Geskin L, Matin R, Beylot-Barry M, Vakeva L, Sanches JA, Servitje O, Weatherhead S, Wobser M, Yoo J, Bayne M, Bates A, Dunnill G, Marschalko M, Buschots AM, Wehkamp U, Evison F, Hong E, Amitay-Laish I, Stranzenbach R, Vermeer M, Willemze R, Kempf W, Cerroni L, Whittaker S, Kim YH, Scarisbrick JJ. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol. 2020 Jun 23.
  • Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid L, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots AM, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro MT, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz PA, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong EK, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Nikolaou V, Quint K, Ram- Wolff C, Rieger K, Stranzenbach R, Szepesi Á, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick JJ; Cutaneous Lymphoma International Consortium (CLIC) insitutions. Treatment of early-stage mycosisfungoides: results from the Prospective Cutaneous Lymphoma International Study (PROCLIPI study). Br J Dermatol. 2020 Jun 1:10.1111/bjd.19252.
  • Phillips D, Schurch CM, Khodadoust MS, Kim YH, Nolan, GP, Jiang S. Hihgly multiplexed phenotyping of immuneregulatory proteins in the tumor microenviornent by CODEX Tissue Imaging. Front Immunol ePUB, May 2021.
  • Phillips D, Matusiak M, Gutierrez B, Bhate S, Barlow G, Jiang S, Demeter J, Smythe K, Pierce R, Fling S, Ramchurren N, Cheever M, Goltsev Y, West R, Khodadoust M, Kim Y, Schurch C, Nolan G. Immune cell topography predicts response to PD-1 blockade in cutaneous T-cell lymphoma. Nat Commun, 2021.
  • Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R. Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation: an ALCANZA sub-analysis. Eur J Cancer 148:411-421, 2021.
  • Beygi S, Sebastian Fernandez-Pol S, Duran G, Wang EB, Henning S, Zehnder JL, Rmchurren N, Fling SP, Cheever MA, Weng WK, Kim YH, Khodadoust MS. Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv 5:771-774, 2021.

For a complete publication of each faculty leader, visit below:

  • Youn Kim, MD
  • Michael Khodadoust, MD, PhD
  • Richard Hoppe, MD, PhD
  • Wen-Kai Weng, MD, PhD